EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Is there a role for the laboratory monitoring in the management of specific antidotes of direct oral anticoagulants?

Nicolas Gendron, Paul Billoir, Virginie Siguret, Véronique Le Cam-Duchez, Valérie Proulle, Laurent Macchi, Elodie Boissier, Christine Mouton, Emmanuel De Maistre, Isabelle Gouin-Thibault, Georges Jourdi, French Society on Thrombosis and Haemostasis

Thrombosis Research · 2024

DOI: 10.1016/j.thromres.2024.04.005 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Thrombosis Research, 2024. Verfasst von Nicolas Gendron und 11 weiteren Autor:innen. Beteiligte Einrichtung: Hematology Department, Assistance Publique Hôpitaux de Paris.Centre-Université de Paris (APHP.CUP), F-75015 Paris, France; Paris Cité University, INS…. Hauptthemen laut MEDLINE: Antidotes, Anticoagulants, Recombinant Proteins, Factor Xa. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 113 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Given the growing number of patients receiving direct oral anticoagulant (DOAC), patients requiring rapid neutralization is also increasing in case of major bleedings or urgent surgery/procedures. Idarucizumab is commercialized as a specific antidote to dabigatran while andexanet alfa has gained the Food and Drug Administration and the European Medicines Agency approval as an oral anti-factor Xa inhibitors antidote. Other antidotes or hemostatic agents are still under preclinical or clinical development, the most advanced being ciraparantag. DOAC plasma levels measurement allows to appropriately select patient for antidote administration and may prevent unnecessary prescription of expensive molecules in some acute clinical settings. However, these tests might be inconclusive after some antidote administration, namely andexanet alfa and ciraparantag. The benefit of laboratory monitoring following DOAC reversal remains unclear. Here, we sought to provide an overview of the key studies evaluating the safety and efficacy of DOAC reversal using the most developed/commercialized specific antidotes, to discuss the potential role of the laboratory monitoring in the management of patients receiving DOAC specific antidotes and to highlight the areas that deserve further investigations in order to establish the exact role of laboratory monitoring in the appropriate management of DOAC specific antidotes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AntidotesAnticoagulantsRecombinant ProteinsFactor XaAntibodies, Monoclonal, HumanizedHumansAdministration, OralFactor Xa InhibitorsDrug Monitoring

Stichwörter der Autor:innen

Andexanet alfaAntidoteCiraparantagDirect oral anticoagulantIdarucizumabLaboratory monitoring

Substanzen

AntidotesAnticoagulantsFactor Xa InhibitorsidarucizumabPRT064445Recombinant ProteinsFactor XaAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Hematology Department, Assistance Publique Hôpitaux de Paris.Centre-Université de Paris (APHP.CUP), F-75015 Paris, France; Paris Cité University, INSERM, Innovative Therapies in Haemostasis, F-75006 Paris, France. Elect…
  • Normandie University, UNIROUEN, INSERM U1096, Rouen University Hospital, Vascular Hemostasis Unit, F 76000 Rouen, France.
  • Paris Cité University, INSERM, Innovative Therapies in Haemostasis, F-75006 Paris, France; Laboratory of Hematology, Lariboisière hospital, AP-HP. Nord, F-75010 Paris, France.
  • Service Hématologie Biologique et UF d'Hémostase Clinique, Hôpital Cochin, Assistance Publique Hôpitaux de Paris.Centre-Université de Paris (APHP.CUP), F-75015 Paris, France; Université Paris Cité, CRC, unité UMR_S1138,…
  • University of Poitiers, INSERM 1313, IRMETIST, F-86000 Poitiers, France; CHU de Poitiers, laboratory of hematology, F-86000 Poitiers, France.
  • Laboratory of Hematology, University Hospital, Nantes, France.

Zitieren

APA

Gendron, N., Billoir, P., Siguret, V., Le Cam-Duchez, V., Proulle, V., Macchi, L., Boissier, E., Mouton, C., De Maistre, E., Gouin-Thibault, I., Jourdi, G., & French Society on Thrombosis and Haemostasis (2024). Is there a role for the laboratory monitoring in the management of specific antidotes of direct oral anticoagulants?. Thrombosis Research. https://doi.org/10.1016/j.thromres.2024.04.005

Vancouver

Gendron N, Billoir P, Siguret V, Le Cam-Duchez V, Proulle V, Macchi L, et al. Is there a role for the laboratory monitoring in the management of specific antidotes of direct oral anticoagulants?. Thrombosis Research. 2024. doi:10.1016/j.thromres.2024.04.005

BibTeX
@article{Gendron2024,
  author = {Gendron, Nicolas and Billoir, Paul and Siguret, Virginie and Le Cam-Duchez, Véronique and Proulle, Valérie and Macchi, Laurent and Boissier, Elodie and Mouton, Christine and De Maistre, Emmanuel and Gouin-Thibault, Isabelle and Jourdi, Georges and French Society on Thrombosis and Haemostasis, French Society on Thrombosis and Haemostasis},
  title = {Is there a role for the laboratory monitoring in the management of specific antidotes of direct oral anticoagulants?},
  journal = {Thrombosis Research},
  year = {2024},
  doi = {10.1016/j.thromres.2024.04.005}
}
Kostenlos starten →